Tango Therapeutics (TNGX) earnings history
Most recent quarter
- Fiscal period
- Q4 2025
- Period end
- Dec 31, 2025
- EPS actual
- −$0.29
- EPS estimate
- −$0.32
- EPS surprise
- +8.86%
- Revenue surprise
- −100.00%
- Revenue
- $0.00
- Revenue estimate
- $500,400.00
- Reported
- Mar 5, 2026
Tango Therapeutics reported Q4 2025 results on March 5, 2026. The company posted a loss of $0.29 per share, narrower than the estimated loss of $0.32, an 8.86% beat. Revenue for the quarter is not shown in the table. A year earlier, in Q4 2024, the loss was $0.35 per share on revenue of $4.1 million.
The table covers 18 quarters, from Q3 2021, and the company lost money in 17 of them. Annual losses were $1.23 per share in 2022, $1.10 in 2023, $1.21 in 2024 and $0.86 in 2025. The one profitable quarter was Q3 2025, at $0.14 per share, when revenue reached $53.8 million, the high in the table. In the other quarters with revenue shown, it ranged from $3.2 million to $19.9 million. The deepest quarterly loss was $0.36, in Q1 2025. Over the 18 quarters shown, Tango beat the EPS estimate 11 times and missed 7 times.
Tango reported Q1 between May 8 and May 12 in each of the past four years. No Q1 2026 results appear in the table yet. When they do, they will show whether losses stay near the recent range of about $0.29 to $0.36 per share outside Q3 2025.
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q4 2025 | Mar 5, 2026 | −$0.32 | −$0.29 | +8.86% | $0.00 | SEC |
| Q3 2025 | Nov 4, 2025 | −$0.05 | $0.14 | +376.68% | $53.8M | SEC |
| Q2 2025 | Aug 5, 2025 | −$0.34 | −$0.35 | −1.80% | $3.2M | SEC |
| Q1 2025 | May 12, 2025 | −$0.35 | −$0.36 | −2.83% | $5.4M | SEC |
| Q4 2024 | Feb 27, 2025 | −$0.34 | −$0.35 | −3.55% | $4.1M | SEC |
| Q3 2024 | Nov 6, 2024 | −$0.37 | −$0.27 | +26.37% | $11.6M | SEC |
| Q2 2024 | Aug 7, 2024 | −$0.35 | −$0.24 | +30.43% | $19.9M | SEC |
| Q1 2024 | May 8, 2024 | −$0.31 | −$0.35 | −12.90% | $6.5M | SEC |
| Q4 2023 | Mar 18, 2024 | −$0.27 | −$0.32 | −16.79% | $5.4M | SEC |
| Q3 2023 | Nov 8, 2023 | −$0.34 | −$0.23 | +31.75% | $10.7M | SEC |
| Q2 2023 | Aug 7, 2023 | −$0.33 | −$0.23 | +29.45% | $14.6M | SEC |
| Q1 2023 | May 9, 2023 | −$0.35 | −$0.32 | +9.01% | $5.8M | SEC |
| Q4 2022 | Mar 27, 2023 | −$0.36 | −$0.33 | +7.04% | $6.4M | SEC |
| Q3 2022 | Nov 10, 2022 | −$0.32 | −$0.33 | −4.20% | $6.9M | — |
| Q2 2022 | Aug 10, 2022 | −$0.32 | −$0.28 | +11.39% | $5.8M | SEC |
| Q1 2022 | May 11, 2022 | −$0.27 | −$0.29 | −6.62% | $5.8M | SEC |
| Q4 2021 | Mar 28, 2022 | −$0.26 | −$0.25 | +5.30% | $5.7M | SEC |
| Q3 2021 | Nov 9, 2021 | −$0.28 | −$0.28 | +1.41% | $6.8M | SEC |
Quarterly revenue
Frequently asked questions
When did Tango Therapeutics (TNGX) last report earnings?
Tango Therapeutics last reported on Mar 5, 2026, covering fiscal Q4 2025.
Did TNGX beat earnings estimates?
Yes. Tango Therapeutics reported EPS of −$0.29 for Q4 2025 against a −$0.32 estimate — a 8.86% beat.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.